Święcki Przemysław, Sawicki Robert, Knapp Małgorzata, Kamiński Karol Adam, Ptaszyńska-Kopczyńska Katarzyna, Sobkowicz Bożena, Lisowska Anna
Department of Cardiology, Medical University of Białystok, 15-276 Białystok, Poland.
J Clin Med. 2020 May 29;9(6):1640. doi: 10.3390/jcm9061640.
Galectin-3 (Gal-3) is a new independent risk factor in the development and severity of coronary artery disease (CAD). The aim of the study was to evaluate whether Gal-3 concentration has prognostic value and if it reflects the progression of atherosclerosis in carotid arteries in patients with CAD after acute myocardial infarction (AMI). The analysis included 110 patients who were hospitalized due to AMI, treated with primary coronary intervention (PCI) and further attended a follow-up visit, and 100 healthy volunteers. The Gal-3 concentration and carotid ultrasound were evaluated at baseline and on a follow-up visit. We found that the Gal-3 concentration in the group with hyperlipidemia decreased during the observation (10.7 vs. 7.9 ng/mL, = 0.00003). Patients rehospitalized during follow up had higher concentration of Gal-3 in the acute phase of myocardial infarction (MI) (10.7 vs. 7.2 ng/mL, = 0.02; 10.1 vs. 8.0 ng/mL, = 0.002, respectively). In the group of patients who had none of the following endpoints: subsequent MI, PCI, coronary artery bypass grafting (CABG) or stroke, there was a decrease in Gal-3 concentration at the follow-up visit. Parameters affecting the frequency of a composite endpoint occurrence are: the presence of atheromatous plaque in the carotid artery ( = 0.017), Gal-3 ( = 0.004) and haemoglobin ( = 0.03) concentration. In multivariate analysis, only Gal-3 concentration higher than 9.2 ng/mL at discharge was associated with a nine-fold increase of risk of composite endpoint occurrence ( = 0.0005, OR = 9.47, 95% CI 2.60-34.45). A significant decrease in Gal-3 concentration was observed in the group of patients after AMI without the endpoint occurrence during observation.
半乳糖凝集素-3（Gal-3）是冠状动脉疾病（CAD）发生发展及严重程度的一个新的独立危险因素。本研究旨在评估Gal-3浓度是否具有预后价值，以及它是否反映急性心肌梗死（AMI）后CAD患者颈动脉粥样硬化的进展情况。分析纳入了110例因AMI住院、接受了急诊冠状动脉介入治疗（PCI）并随后接受随访的患者，以及100名健康志愿者。在基线期和随访时评估了Gal-3浓度及颈动脉超声情况。我们发现，高脂血症组的Gal-3浓度在观察期间有所下降（10.7 vs. 7.9 ng/mL，P = 0.00003）。随访期间再次住院的患者在心肌梗死（MI）急性期的Gal-3浓度更高（分别为10.7 vs. 7.2 ng/mL，P = 0.02；10.1 vs. 8.0 ng/mL，P = 0.002）。在没有出现以下任何终点事件的患者组中：后续MI、PCI、冠状动脉搭桥术（CABG）或中风，随访时Gal-3浓度有所下降。影响复合终点事件发生频率的参数有：颈动脉粥样斑块的存在（P = 0.017）、Gal-3（P = 0.004）和血红蛋白（P = 0.03）浓度。多因素分析中，仅出院时Gal-3浓度高于9.2 ng/mL与复合终点事件发生风险增加9倍相关（P = 0.0005，OR = 9.47，95%CI 2.60 - 34.45）。在观察期间未出现终点事件的AMI患者组中，Gal-3浓度显著下降。
